While the pharma giant Eli Lilly has lagged behind the broader market over the past year, it has outpaced the health care space, and analysts remain strongly bullish on the stock’s prospects.

Pfizer filed a second lawsuit yesterday accusing Danish drugmaker Novo Nordisk of structuring its US$9 billion (RM37.8 ...

Pfizer filed a second lawsuit on Monday accusing Danish drugmaker Novo Nordisk of structuring its $9 billion bid for Metsera ...

Novo Nordisk's new CEO is set to face intense investor scrutiny this week as the Wegovy-maker shakes up its board and pursues ...

November, single-dose vials of the popular weight-loss jab—Zepbound (tirzepatide)—will be available to buy from Walmart pharmacies across the U.S., thanks to a new collaboration between the retailer ...

Metsera's shareholders are scheduled to meet on November 13 to decide on Novo Nordisk's offer of around $8.5 billion, while ...

The partnership between LillyDirect and Walmart allows patients to pick up Zepbound at Walmart pharmacies at the same self-pay price as online. Sel ...

A rendering of Eli Lilly's planned plant expansion in Pleasant Prairie. The company is preparing for a next phase on a site ...

The GLP-1 drug market has surged dramatically in the past four years, driven by soaring demand for weight-loss treatments ...

Pfizer has now filed a suit in federal court, following its claim in state court on Friday. It is riding Trump-era political ...

Determining the type of diabetes a patient has at diagnosis can be challenging, and health care professionals should focus on each patient’s clinical condition when determining initial treatment, ...

The healthcare industry has proven to be a resilient place for investors to put cash to work over the years. If you are ...